MedTrace Logo

Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

NCT00675077 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2009-01-05

No results posted yet for this study

Summary

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.

This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Conditions

  • Huntington Disease

Interventions

RADIATION

Far Infrared Radiation

Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Sponsors & Collaborators

  • GAAD Medical Research Institute Inc.

    lead OTHER

Principal Investigators

  • Ken Nedd, M.D. · GAAD Medical Research Institute Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-05-31
Completion
2010-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00675077 on ClinicalTrials.gov